Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.

On Monday, Roivant said it had agreed to invest $116 million in Arbutus Biopharma, a small biotech company focusing on hepatitis B that is locked in a proxy war with Moderna over a liquid ...

Baltimore County Police officers did not record a fatal Wednesday encounter during which one officer shot a bow-wielding man in Arbutus, according to state investigators. The officer who fatally ...

(Reuters) -A U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies' legal fight over Moderna's ...

While Arbutus Biopharma is busy scrapping with Moderna and Pfizer over COVID-19 vaccine patents, Moderna has chalked up a win in a separate case. Back in 2018, Moderna challenged one of Arbutus ...

Arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for infringement of U.S. patents related to Moderna's COVID-19 vaccine.

Roivant's shares gained 4% in afternoon trading, while its subsidiary Arbutus rose more than 17%. In a so-called "claim construction order", U.S. District Judge Mitchell Goldberg interpreted parts ...